Helen Robinson

Company: Artios Pharma
Job title: Vice President of Biology
Seminars:
Exploring Polθ as a New DDR Target 5:00 pm
Discovery and preclinical development of first-in-class inhibitors for oncology in a PARP-resistant setting Leveraging synthetic lethality and understanding of the theta-mediated end joining (TMEJ) to determine a validated target Latest from the lab, clinical validation, and future directions Discussing how it will compare to PARP Dissecting how to leverage it as a novel target Combination…Read more
day: Day One